Abstract-Chromaffin granule transmitters such as chromogranin A and catecholamines have been used in the diagnosis of pheochromocytoma, but the diagnostic and prognostic value of chromogranin A have not been explored in malignant pheochromocytoma. We evaluated these transmitters in patients with pheochromocytoma (nϭ27), both benign (nϭ13) and malignant (nϭ14). Patients with benign pheochromocytoma were studied before and after surgical excision (nϭ6), whereas patients with malignant pheochromocytoma were evaluated before and after combination chemotherapy with regular cycles of cyclophosphamide/dacarbazine/vincristine (nonrandomized trial in nϭ9). During treatment, patient responses to chemotherapy were divided according to anatomic and clinical criteria: responders (nϭ5) versus nonresponders (nϭ4). Plasma chromogranin A rose progressively (PϽ0.0001) from control subjects (48.0Ϯ3.0 ng/mL) to benign pheochromocytoma (188Ϯ40.5 ng/mL) to malignant pheochromocytoma (2932Ϯ960 ng/mL). Parallel changes were seen for plasma norepinephrine (PϽ0.0001), though plasma epinephrine was actually lower in malignant than benign pheochromocytoma (Pϭ0.0182). In bivariate analyses, chromogranin A, norepinephrine, and epinephrine discriminated between pheochromocytoma and control subjects (all PϽ0.0001), whereas in a multivariate analyses, norepinephrine was the best discriminator (Pϭ0.011). Chromogranin A was significantly different in benign versus malignant pheochromocytoma on both bivariate (Pϭ0.0003) and multivariate (Pϭ0.011) analyses. After excision of benign pheochromocytoma, chromogranin A (Pϭ0.028), norepinephrine (Pϭ0.047), and epinephrine (Pϭ0.037) all fell to values near normal. During chemotherapy of malignant pheochromocytoma (nϭ9), plasma chromogranin A (Pϭ0.047) and norepinephrine (Pϭ0.02) fell but not epinephrine. In 5 responders to chemotherapy, there were significant declines in chromogranin A (Pϭ0.03) and norepinephrine (Pϭ0.03) but not epinephrine; in 4 nonresponders, none of the transmitters changed. Plasma chromogranin A varied longitudinally with tumor response and relapse. We conclude that plasma chromogranin A is an effective tool in the diagnosis of pheochromocytoma, and markedly elevated chromogranin A may point to malignant pheochromocytoma. During chemotherapy of malignant pheochromocytoma, chromogranin A can be used to gauge tumor response and relapse. (Hypertension. 2000;36:1045-1052.)
M alignant pheochromocytoma presents several difficulties in management, both in diagnosis 1,2 and in effective treatment. [2] [3] [4] Even after excision, the diagnosis of malignant pheochromocytoma cannot be made reliably on histological grounds 2 ; thus, extensive evaluations of tumor location are required to ascertain the presence of local or distant invasion or metastases by either surgical exploration, imaging, or regional venous blood sampling. 2 Specific biochemical diagnosis of malignant pheochromocytoma has received only limited attention. 1 Once diagnosed, metastatic pheochromocytoma may be effectively treated. 3, 4 In analogy to neuroblastoma, 4 combination chemotherapeutic regimens involving cyclophosphamide/dacarbazine/vincristine have been developed for malignant pheochromocytoma 3, 4 ; when regularly scheduled and dose-escalated to the threshold of hematological toxicity, such regimens may result in effective (though temporary) remission in more than half of such patients 3, 4 ; during these regimens, urinary catecholamine excretion has previously been used to estimate clinical response. 3, 4 Chromogranin A is an acidic protein costored and coreleased by exocytosis, along with catecholamines from chromaffin granules of normal adrenal medulla 5, 6 and pheochromocytoma. 7, 8 In this study, we evaluated the utility of plasma concentrations of chromaffin granule transmitters (chromogranin A, norepinephrine, and epinephrine) in the management of pheochromocytoma, both diagnostic and therapeutic. Our results indicate that measurement of plasma chromogranin A is useful in the diagnosis of pheochromocytoma, and a markedly elevated chromogranin A may suggest the diagnosis of malignant pheochromocytoma. Chromogranin A may also assist in ascertaining the response to chemotherapy in malignant disease.
Methods

Patients
The study was approved by the institutional review boards, and patients gave informed consent. Plasma samples were obtained from 14 patients with malignant pheochromocytoma. Malignancy was documented by metastatic disease to the retroperitoneum, bone, lung, mediastinum, lymph nodes, spleen, or other sites. The mean age was 40.4 years (range, 16 to 64), and there was an 11:3 male/female predominance. The primary tumor arose from the adrenal gland(s) in 7 patients and from extra-adrenal sites in 7 patients. One patient had Von Hippel-Lindau syndrome. Nine of these patients underwent combination chemotherapy (see below), with mean and median intervals between the initial pathological diagnosis and the first chemotherapy treatment of 48.2 and 26 months, respectively.
Thirteen patients with benign pheochromocytoma were also evaluated, with postresection data available on 6. The mean age was 36.5 (range, 16 to 60) years, and there was a 10:3 female/male predominance (11 white, 2 black). Eleven benign tumors were intra-adrenal: 6 unilateral (4 right, 2 left) and 5 bilateral. The other 2 benign tumors were extra-adrenal (1 in the urinary bladder and 1 bilateral and extra-adrenal). Two benign tumors were familial, both with multiple endocrine neoplasia type 2. One patient had Cushing's syndrome, which subsided on resection of the pheochromocytoma. In benign pheochromocytoma, treatment consisted of surgical resection.
Forty-nine normal control subjects (for chromogranin A) and 178 other normal control subjects (for norepinephrine and epinephrine) were studied.
The diagnosis of pheochromocytoma was made clinically, biochemically, and histologically. 3, 4 Because no reliable gross or microscopic features distinguish benign from malignant pheochromocytoma, the diagnosis of malignant pheochromocytoma was based on the presence of regional or distant metastases. 3, 4, 9 Some features of 12 of these 14 malignant pheochromocytoma patients were reported previously. 4 
Assays
The plasma concentration of chromogranin A was measured by a rapid modification of a soluble-phase, double-antibody radioimmunoassay, based on the protein isolated from pheochromocytoma chromaffin granules. 10 -16 Plasma norepinephrine and epinephrine concentrations were measured by liquid chromatography with electrochemical detection. 17, 18 The lower limit of detection of plasma epinephrine was 5 pg/mL. (To convert chromogranin A from ng/mL to g/L, multiply by 1.0. To convert epinephrine from pg/mL to pmol/L, multiply by 5.458. To convert norepinephrine from pg/mL to nmol/L, multiply by 0.005911.)
Treatment of Malignant Pheochromocytoma
Before treatment with combination chemotherapy, specific antihypertensive therapy was administered to patients to maintain normal blood pressure. Initial treatment consisted of oral phenoxybenzamine, usually in combination with a ␤-adrenergic blocker, either propranolol or atenolol. The catecholamine synthesis inhibitor ␣-methyl-para-tyrosine was also administered orally, as previously described. 3, 4 Combination chemotherapy 3, 4 was administered to 9 of the 14 patients with malignant pheochromocytoma. The combination chemotherapy regimen consisted of intravenous cyclophosphamide, 750 mg/m 2 body surface area on day 1; vincristine, 1.4 mg/m 2 on day 1; and dacarbazine, 600 mg/m 2 on days 1 and 2. The combination was repeated on a 21-day cycle; hematologic toxicity (leukopenia) prompted either a treatment delay of 1 week or appropriate downward dosage modifications. If there was no significant hematologic toxicity, the doses of cyclophosphamide and dacarbazine were increased by 10% at each cycle until myelosuppression was seen. To monitor for possible hemodynamic or endocrine complications of chemotherapy, all patients received their first treatment while hospitalized. Subsequent treatment cycles were on an outpatient basis. The patients' responses to therapy were divided by 2 criteria: tumor (anatomic) response and biochemical response. Anatomic response was judged according to modified standard criteria 3, 4 and classified as complete response (complete regression of all clinical evidence of disease, including resolution of all palpable and radiologic abnormalities); partial response (Ն50% reduction of all measurable tumor); minimal response (Ն25% but not Ͼ50% reduction of all measurable tumor); no change; and progression (the appearance of a new lesion or an increase of 25% in any measurable tumor). Change in tumor size was determined from 2 measurement periods at least 4 weeks apart and calculated by the product of 90°cross-perpendicular diameters at their greatest length. Biochemical responses were initially based on 24-hour urinary determinations of free catecholamines, metanephrines, and vanillylmandelic acid and were defined as complete response (return to normal values); partial response (Ն50% reduction); minimal change; and progression (an increase of Ն25% in all 3 measurements). The patients were followed longitudinally until evidence of progressive disease, at which time therapy was discontinued.
The 9 patients with chemotherapy-treated malignant pheochromocytoma in this study were divided into 2 groups according to the clinical response to chemotherapy: a "no response" group (nϭ4, including minor or no response) and a "response" group (nϭ5, including complete or partial response). Plasma samples for chromogranin A, norepinephrine, and epinephrine were obtained both before treatment and after treatment, at the time of maximal tumor regression. Posttreatment biochemical nadir values were analyzed. Two patients with malignant pheochromocytoma were also subjected to surgical "debulking" of their malignant pheochromocytoma tumor masses; their results were not included in the analysis of chemotherapy response.
Statistical Analyses
Data are reported as meanϮ1 SEM. Several statistical methods were used, both parametric (1-way ANOVA, t tests) and nonparametric (Mann-Whitney U test, Wilcoxon signed rank test). After ANOVA, post hoc comparisons of 2 groups were performed by the Bonferroni procedure in SPSS (Statistical Package for the Social Sciences) to guard against inappropriate conclusions drawn from multiple comparisons. Nonparametric tests were used if the sample size was very small (Ͻ10) or if the data were not distributed normally. Two-tailed tests were used unless a prior directional hypothesis was tested. Probability values of Յ0.05 were considered significant. Simultaneous-model, multiple linear regression analysis was performed in SPSS to assess the relative diagnostic value of several independent variables; during stepwise multiple linear regression, criteria for retention or exclusion of an independent variable from the model were significance levels of ␣ϭ0.05. For analysis of treatment (surgery of chemotherapy) effects, posttreatment nadir values were used. Analyses were performed in the programs Excel (Microsoft), InStat (GraphPad Software), or SPSS (Statistical Package for the Social Sciences).
Results
Diagnosis of Pheochromocytoma
ANOVA
Chromogranin A (Fϭ20.3, PϽ0.0001), norepinephrine (Fϭ107, PϽ0.0001), and epinephrine (Fϭ41.2, PϽ0.0001) were markedly elevated in patients with pheochromocytoma (Table 1) . For chromogranin A and norepinephrine, there were progressive rises in plasma concentration from normal control subjects (nϭ178) to benign pheochromocytoma (nϭ13), to malignant pheochromocytoma (nϭ14). For epinephrine, concentrations were highest in patients with benign pheochromocytoma (670Ϯ267 pg/mL).
Pheochromocytoma Versus Control
To test which biochemical variables best distinguished patients with pheochromocytoma (all nϭ27; nϭ13 benign plus nϭ14 malignant) from control subjects without pheochromocytoma, we used both bivariate (simple) and multivariate methods. In bivariate analyses, pheochromocytoma patients differed from control subjects in chromogranin A (1611Ϯ558 versus 48. In a multivariate analysis, incorporating the same 6 plasma biochemical independent variables (chromogranin A, norepinephrine, epinephrine, or their ratios [chromogranin A/norepinephrine, chromogranin A/epinephrine, norepinephrine/ epinephrine]), only a marginally significant model emerged (multiple Rϭ0. 565 Table 1 ): chromogranin A, 48.0Ϯ3.0 ng/mL; norepinephrine, 200Ϯ7.8 pg/mL; epinephrine, 18.0Ϯ1.5 pg/mL. Lower limit of detection for plasma epinephrine is 5 pg/mL. (To convert chromogranin A from ng/mL to g/L, multiply by 1.0. To convert epinephrine from pg/mL to pmol/L, multiply by 5.458. To convert norepinephrine from pg/mL to nmol/L, multiply by 0.005911.) On inspection of Figure 1 , it can be seen that a chromogranin A value of Ͼ600 ng/mL was observed only in subjects with malignant pheochromocytoma (in 8 of 14 [57%] of subjects with malignant disease).
In patients with pheochromocytoma (benign plus malignant grouped together), chromogranin A correlated inversely with epinephrine (Figure 2 ; Spearman rϭϪ0.378, nϭ27, Pϭ0.026).
In a multivariate analysis, we tested which of these 6 plasma biochemical independent variables (chromogranin A, norepinephrine, epinephrine, or their ratios [chromogranin A/norepinephrine, chromogranin A/epinephrine, norepinephrine/epinephrine]) differed between benign and malignant disease. By stepwise multiple linear regression, the most significant biochemical difference between malignant and benign disease was chromogranin A (multiple Rϭ0.482, adjusted R 2 ϭ0.202, Fϭ7.56, Pϭ0.011).
Response to Treatment
Surgery for Benign Pheochromocytoma
Six patients with benign pheochromocytoma underwent resection of the tumor, with plasma sampling before and after operation ( Figure 3) ; postoperative nadir values were analyzed (samples obtained at 4.1Ϯ2.0 [range, 0.7 to 13.5] months after resection). Chromogranin A declined by Ϸ79% (from 191Ϯ62 to 41Ϯ6.2 ng/mL; Pϭ0.028), norepinephrine by Ϸ87% (from 3500Ϯ1439 to 439Ϯ172 pg/mL; Pϭ0.047), and epinephrine by Ϸ78% (from 288Ϯ101 to 64Ϯ41 pg/mL; Pϭ0.037) to values within or near the normal ranges ( Figure 3 ). Table 1 Because the anatomic and clinical responses to chemotherapy were variable from patient to patient, we then analyzed biochemical responses in patient groups stratified by response (nϭ5 responders, nϭ4 nonresponders). In the chemotherapy responders (nϭ5), there were significant declines ( Figure 5 ) in chromogranin A (from 867Ϯ439 to 78.4Ϯ20 ng/mL, Pϭ0.03) and norepinephrine (from 9983Ϯ3442 to 909Ϯ304 pg/mL, Pϭ0.03) but not epinephrine (from 317Ϯ234 to 70.4Ϯ18 pg/mL, Pϭ0.31). In the 4 nonresponders to chemotherapy ( Figure 5) , none of the transmitters changed significantly (all Pϭ0.13). Once again, post-chemotherapy nadir values were analyzed (in the 4 nonresponders, samples were analyzed at 6.6Ϯ1.1 [range, 4 to 9] months after initiation of treatment; in the 5 responders, samples were analyzed at 13.2Ϯ2.5 [range, 6.5 to 22] months after initiation of treatment).
Chemotherapy for Malignant Pheochromocytoma
What initial transmitter values best predicted the subsequent response to chemotherapy in these 9 patients? In bivariate analyses, responders differed from nonresponders in epinephrine (317Ϯ234 versus 4.75Ϯ0.25 pg/mL, Pϭ0.02) and in chromogranin A/epinephrine ratio (28.7Ϯ23.9 versus 773Ϯ420 ng/pg, Pϭ0.03) but not chromogranin A (867Ϯ439 versus 3867Ϯ2102 ng/mL, Pϭ0.37), norepinephrine (9983Ϯ3442 versus 4615Ϯ1757 pg/mL, Pϭ0.20), or the ratios of chromogranin A/norepinephrine (0.09Ϯ0.02 versus 4,10Ϯ3.33 ng/pg, Pϭ0.45) or norepinephrine/epinephrine (503Ϯ414 versus 923Ϯ351 pg/pg, Pϭ0.14).
In multivariate analyses, the 6 biochemical independent variables (chromogranin A, norepinephrine, epinephrine, and their ratios) did not significantly predict the response to chemotherapy in these 9 patients (Rϭ0.751, R 2 ϭ0.564, adjusted R 2 ϭϪ0.742, Fϭ0.432, Pϭ0.820), and a better model was not obtained by stepwise multiple linear regression. Figure 6 displays biochemical responses to chemotherapy in individual patients with malignant pheochromocytoma. One patient ( Figure 6A ) had a clinical and anatomic response to chemotherapy: Although his chromogranin A was initially elevated (619 ng/mL), it fell gradually in response to repeated cycles of chemotherapy, and by 4 to 6 months (6 to 9 chemotherapy cycles), it had stabilized at 45 to 55 ng/mL, within the normal range. Another patient ( Figure 6B ) displayed an initial anatomic response to chemotherapy, and although pretreatment chromogranin A was markedly elevated at 2753 ng/mL, by 13 to 17 months it had fallen to 60 to 66 ng/mL, values within the normal range; by 25 months, however, anatomic relapse occurred, with reelevation of chromogranin A to 2228 ng/mL.
Surgery for Malignant Pheochromocytoma
Two patients with malignant pheochromocytoma were subjected to operation ("debulking"). Both had declines in chromogranin A. In 1 patient, preoperative biochemistries were chromogranin A 10211 ng/mL, norepinephrine 5760 pg/mL, and epinephrine Ͻ5 pg/mL; 25-day postoperative values were chromogranin A, 800 ng/mL; norepinephrine, 4095 pg/mL; and epinephrine, Ͻ5 pg/mL. In 1 patient, preoperative biochemistries were chromogranin A, 2460 ng/mL; norepinephrine, 786 pg/mL; and epinephrine, Ͻ5 pg/mL; 17-day postoperative values were chromogranin A, Figure 5 . Changes in chromaffin granule transmitter concentrations in plasma after intravenous combination chemotherapy for malignant pheochromocytoma, stratified by response to chemotherapy: nϭ5 patients with response to chemotherapy versus nϭ4 patients with no response to chemotherapy. Post-chemotherapy nadir values were analyzed (in 4 nonresponders, samples obtained at 6.6Ϯ1.1 [range, 4 to 9] months after initiation of treatment; in 5 responders, samples obtained at 13.2Ϯ2.5 [range, 6.5 to 22] months after initiation of treatment). Normal ranges (see Table 1 
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Discussion
Although pheochromocytoma is an unusual cause of hypertension, occurring in perhaps Ϸ0.05% of cases, 2,9,19 -21 it is among the best-understood causes of hypertension and may be successfully removed surgically in Ն90% of patients but will eventually be lethal in most untreated cases. Early diagnosis is therefore important, not only to avoid hypertensive complications but also because of the Ϸ10% incidence of malignancy. 2, 9 Although urinary catecholamines are useful for the diagnosis of pheochromocytoma, [22] [23] [24] combined biochemical tests on blood samples may offer the advantages of patient convenience and enhanced sensitivity. 1, 7, 20, 21 
Diagnosis of Pheochromocytoma
We found a progressive rise (PϽ0.0001) in plasma chromogranin A, from control subjects to benign pheochromocytoma to malignant pheochromocytoma, with a parallel rise (PϽ0.0001) in plasma norepinephrine but higher epinephrine in benign than malignant pheochromocytoma (Table 1 ).
In the diagnosis of pheochromocytoma in general (benign or malignant), bivariate analyses found distinctions between control subjects and patients with pheochromocytoma (Table  1) for plasma chromogranin A (PϽ0.0001), norepinephrine (PϽ0.0001), and epinephrine (PϽ0.0001), whereas stepwise multiple linear regression identified plasma norepinephrine as the single most important variable in this diagnostic distinction (adjusted R 2 ϭ0.149, Fϭ7.14, Pϭ0.011). Bravo and Gifford 20 have also emphasized the particular diagnostic value of plasma norepinephrine in pheochromocytoma.
Benign Versus Malignant Pheochromocytoma
In studying the characteristics of malignant versus benign pheochromocytoma (Table 1 and Figure 1) , both plasma chromogranin A (Pϭ0.0003) and norepinephrine (Pϭ0.0344) were higher in malignant than benign pheochromocytoma, though plasma epinephrine was actually lower (Pϭ0.0182) in malignant tumors. In a stepwise multivariate analysis of chromaffin granule transmitter concentrations, plasma chromogranin A elevation proved to be the most significant difference between benign and malignant tumor behavior (adjusted R Because of metastases and local tissue invasion, malignant pheochromocytomas typically have much greater tumor mass than benign pheochromocytomas 2, 9 ; hence, the extreme chromogranin A values seen in malignant pheochromocytoma ( Figure 1 ) may simply reflect the greater tumor burden in these patients. Indeed, in patients with both benign and malignant pheochromocytomas, we have previously found that plasma chromogranin A correlates with the weight of the excised tumor. 7, 8 There is little previous literature comparing plasma epinephrine in benign versus malignant pheochromocytomas. 1, 2, 9 Because phenylethanolamine N-methyltransferase is a glucocorticoid-responsive enzyme, 25 very large or extraadrenal pheochromocytomas may be relatively deficient in epinephrine because the chromaffin cells in such tumors are not in close apposition to glucocorticoid-producing adrenal cortical cells. The quantity of catecholamine release by pheochromocytoma may be an unreliable gauge of tumor size because there is substantial intratumoral catecholamine metabolism, resulting in even some large pheochromocytomas with relatively modest catecholamine release. 1, 2, 21 The inverse correlation of plasma chromogranin A and epinephrine in pheochromocytoma, benign or malignant (Figure 2 ; Spearman rϭϪ0.378, nϭ27, Pϭ0.026), was initially unexpected because both chromogranin A and phenylethanolamine N-methyl transferase (the enzyme catalyzing the formation of epinephrine) are found in chromaffin cells, and each is glucocorticoid responsive. 26 However, as noted above, chromaffin cells in malignant pheochromocytomas, by virtue Table 1 ): chromogranin A, 48.0Ϯ3.0 ng/mL; norepinephrine, 200Ϯ7.8 pg/mL; epinephrine, 18.0Ϯ1.5 pg/mL. (To convert chromogranin A from ng/mL to g/L, multiply by 1.0. To convert epinephrine from pg/mL to pmol/L, multiply by 5.458. To convert norepinephrine from pg/mL to nmol/L, multiply by 0.005911.)
of tumor size and metastases, are unlikely to be in close apposition to the adrenal cortex, the source of glucocorticoid delivery to the adrenal medulla; hence, shear tumor mass may be an overriding determinant of plasma chromogranin A in pheochromocytoma 7, 8 or neuroblastoma, 27 whereas epinephrine secretion is likely to be prominent only from small intra-adrenal pheochromocytomas.
Other pheochromocytoma secretory products may aid in the distinction between benign and malignant pheochromocytoma: For example, substantial elevation in the plasma concentration of the catecholamine precursor DOPA ([L]-dihydroxyphenylalanine) may suggest malignancy in pheochromocytoma, 1 raising the possibility of especially severe derangements in catecholamine biosynthesis (or relative loss of DOPA decarboxylase activity) within such tumors. 1, 28 Helman et al 29 reported that neuropeptide Y mRNA is less frequently expressed in malignant than in benign pheochromocytomas, whereas de Senanayake et al 30 found higher plasma neuropeptide Y concentrations in adrenal than in extra-adrenal pheochromocytomas. The role of plasma neuropeptide Y in distinguishing benign from malignant pheochromocytoma has not yet been explored. Plasma metanephrine concentration is a highly sensitive and specific approach to pheochromocytoma diagnosis, and metanephrines correlate with pheochromocytoma size 31 ; hence, plasma metanephrines might also be useful in discriminating malignant from benign disease.
Treatment of Pheochromocytoma
Benign Pheochromocytoma
In 6 patients with benign pheochromocytoma, surgical excision of the tumor resulted in normalization of all neurotransmitter concentrations (Figure 3 ).
Malignant Pheochromocytoma
When 9 patients with malignant pheochromocytoma were subjected to repeated cycles of combination chemotherapy (Figure 4 ), chromogranin A (Pϭ0.047) and norepinephrine (Pϭ0.02) but not epinephrine (Pϭ0.129) fell in the group as a whole, but the substantial clinical and anatomic heterogeneity of chemotherapy responses (Figure 4 ) prompted us to analyze the results in patients stratified by anatomic and clinical response to chemotherapy.
After chemotherapy (Table 2 and Figure 5 ), the 5 responders showed declines in chromogranin A (by Ϸ91%, Pϭ0.03) and norepinephrine (also by Ϸ91%, Pϭ0.03) but not epinephrine (Pϭ0.31). By contrast, the 4 nonresponders showed no significant decline in any of the transmitters (all Pϭ0.13); indeed, each transmitter tended to rise, though the number of subjects was too small to achieve statistical significance. 32 Bivariate (but not multivariate) analyses identified 2 biochemical parameters that predicted a favorable response to chemotherapy: plasma epinephrine (317Ϯ234 versus 4.75Ϯ0.25 pg/mL, Pϭ0.02) and the ratio of chromogranin A/epinephrine (28.7Ϯ23.9 versus 773Ϯ420 ng/pg, Pϭ0.03).
The progress of 2 individual patients with malignant pheochromocytoma (Figure 6 ) is illustrative of how plasma chromogranin A and norepinephrine paralleled the clinical and anatomic response to chemotherapy. One patient ( Figure  6A ) whose chromogranin A and norepinephrine showed a sustained fall after treatment did well; however, a substantial rise in chromogranin A and norepinephrine after an initial fall was associated with disease relapse ( Figure 6B) .
Previously, we noted that plasma chromogranin A also conveys diagnostic and prognostic information in children with neuroblastoma 27 : Plasma chromogranin A increased progressively with advances in disease stage (ie, tumor burden), and stratification by degree of plasma chromogranin A elevation predicted survival. (To convert chromogranin A from ng/mL to g/L, multiply by 1.0. To convert epinephrine from pg/mL to pmol/L, multiply by 5.458. To convert norepinephrine from pg/mL to nmol/L, multiply by 0.005911.)
Values represent meanϮ1 SEM. *Versus pretreatment, PϽ0.05. Posttreatment nadir values were analyzed. In the 4 nonresponders, postchemotherapy samples were obtained at 6.6Ϯ1.1 (range, 4 to 9) months after initiation of treatment; in the 5 responders, postchemotherapy samples were obtained in 13.2Ϯ2.5 (range, 6.5 to 22) months after initiation of treatment. Normal ranges (see Table 1 ): chromogranin A, 48.0Ϯ3.0 ng/mL; norepinephrine, 200Ϯ7.8 pg/mL; epinephrine, 18.0Ϯ1.5 pg/mL. Paired comparisons were made by the nonparametric Wilcoxon signed rank test (1-tailed test).
In conclusion, plasma chromogranin A is an effective tool in the diagnosis of pheochromocytoma as well as in the distinction between benign and malignant pheochromocytoma. During chemotherapy of malignant pheochromocytoma, chromogranin A can be used to gauge tumor response and relapse.
